Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Activating epidermal growth factor receptor (EGFR) mutations are prevalent in glioblastoma, but clinical responses to EGFR inhibitors are limited.
• The precise mechanisms driving resistance and tumor progression in EGFR-mutated glioblastoma remain incompletely understood.

Purpose of the Study:

• To investigate the role of Src family kinases (SFKs) as effectors of oncogenic EGFR signaling in glioblastoma.
• To evaluate the therapeutic potential of targeting SFKs, alone and in combination with anti-EGFR therapies, for glioblastoma treatment.

Main Methods:

• Utilized gene silencing and pharmacological inhibition (dasatinib) to assess the impact of SFKs on EGFR-driven tumor cell motility and survival.
• Employed an orthotopic glioblastoma model expressing EGFRvIII to evaluate in vivo efficacy of dasatinib and anti-EGFR monoclonal antibody (mAb 806).
• Examined clinical glioblastoma samples for coactivation of EGFR and SFKs.

Main Results:

• Oncogenic EGFR signaling, including EGFRvIII, activates Fyn and Src, promoting glioblastoma cell invasion and survival.
• Gene silencing of Fyn and Src significantly reduced EGFR- and EGFRvIII-dependent tumor cell motility.
• Dasatinib inhibited invasion, induced tumor regression and apoptosis, and prolonged survival in an EGFRvIII glioblastoma model.
• Combination therapy with dasatinib and mAb 806 demonstrated enhanced anti-tumor efficacy and survival benefits.
• Clinical samples revealed frequent coactivation of EGFR and SFKs in glioblastoma patients.

Conclusions:

• Src family kinases (Fyn and Src) are critical downstream effectors of oncogenic EGFR signaling in glioblastoma.
• Targeting SFKs with inhibitors like dasatinib represents a promising therapeutic strategy for glioblastoma.
• Combined inhibition of EGFR and SFKs offers a rationale for developing novel, more effective glioblastoma treatments.